DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine

Clinical Trial Summary

The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.

See also
Status	Clinical Trial	Phase
Completed	`NCT01250470` - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma	Phase 1
Completed	`NCT01922076` - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT01765088` - A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Phase 3
Suspended	`NCT01386710` - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma	Phase 1/Phase 2
Terminated	`NCT01227434` - A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma	Phase 2
Completed	`NCT01171469` - Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor	Phase 1
Active, not recruiting	`NCT00995007` - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas	Phase 2
Not yet recruiting	`NCT06333899` - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Early Phase 1
Completed	`NCT00879437` - Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma	Phase 2
Active, not recruiting	`NCT01204684` - Dendritic Cell Vaccine for Patients With Brain Tumors	Phase 2
Recruiting	`NCT03370926` - FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy	N/A
Recruiting	`NCT04541082` - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Phase 1
Completed	`NCT00390299` - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1
Recruiting	`NCT01837862` - A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	Phase 1/Phase 2
Recruiting	`NCT01269853` - Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA	Phase 1/Phase 2
Completed	`NCT00612651` - PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas	Phase 1
Terminated	`NCT03332355` - Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2	Phase 1
Completed	`NCT03043391` - Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	Phase 1
Active, not recruiting	`NCT03581292` - Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations	Phase 2
Recruiting	`NCT03975829` - Pediatric Long-Term Follow-up and Rollover Study	Phase 4

NCT number	NCT06264388
Study type	Interventional
Source	University of Miami
Contact	Leonela Wright, MSN, RN
Phone	305-243-0864
Email	lxw612@med.miami.edu
Status	Recruiting
Phase	Phase 2
Start date	May 1, 2024
Completion date	May 1, 2034

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms